Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Illumina gains on Affymetrix settlement

Illumina (NASDAQ:ILMN) gained $9.57 (16%) to $70.02 on Thursday after the microarray and genetic services company agreed to pay Affymetrix (NASDAQ:AFFX)

Read the full 219 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE